Logo
x

Search

Subscribe Now

Ovarian Cancer

PharmaShots Interview: Vigeo Therapeutics' Dr. Lou Vaickus and Dr. Jing Watnick Share Insights on VT1021 Data Presented at SITC 2020

PharmaShots Interview: Vigeo Therapeutics' Dr. Lou Vaickus and Dr. Jing Watnick Share Insights on VT1021 Data Presented at SITC 20...

  • January 15, 2021
AstraZeneca and MSD's Lynparza (olaparib) Receive EU's Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

AstraZeneca and MSD's Lynparza (olaparib) Receive EU's Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Canc...

  • November 6, 2020
GSK's Zejula (niraparib) Receives EC's Approval as a Treatment in Advanced Ovarian Cancer

GSK's Zejula (niraparib) Receives EC's Approval as a Treatment in Advanced Ovarian Cancer

  • October 30, 2020
AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mutated Ovarian Cancer

AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mut...

  • September 18, 2020
Roche Reports Results of Tecentriq in P-III IMagyn050 Study for Women with 1L Newly Diagnosed Advanced Stage Ovarian Cancer

Roche Reports Results of Tecentriq in P-III IMagyn050 Study for Women with 1L Newly Diagnosed Advanced Stage Ovarian Cancer

  • July 13, 2020
GSK's Zejula (niraparib) Receives the US FDA's Approval as 1L Monotherapy Maintenance Treatment for Women with Advanced Ovarian Cancer Regardless of Biomarker Status

GSK's Zejula (niraparib) Receives the US FDA's Approval as 1L Monotherapy Maintenance Treatment for Women with Advanced Ovarian Ca...

  • April 30, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.